When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
TPTX - Turning Point Solid Tumor Data And Other News: The Good Bad And Ugly Of Biopharma
Turning Point Therapeutics Inc.
Turning Point reports positive data for tumor drug candidate
Turning Point Therapeutics (TPTX) reported positive preliminary data from its Phase 2 clinical trial TRIDENT-1. The trial is designed to assess the potential of repotrectinib in treating patients with ALK-, ROS1- or NTRK-3-mutation-positive solid tumors. The data cutoff date was July 10, 2020. The drug candidate was also found to be generally well-tolerated.
The early Phase 2 TRIDENT-1 dataset includes the first 39 treated patients who have had at least one post-baseline scan. A subsequent scan was done at least 28 days later to